Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...
As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...
MJH Life Sciences®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, a preeminent ...
The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...
The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...
The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.
The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.
The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback